PURPOSE: Age-related macular degeneration (AMD) is a common cause of irreversible vision loss in the elderly. The hypothesis was that in vitro stimulation of RPE cells with Abeta(1-40), a constituent of drusen, promotes changes in gene expression and cellular pathways associated with the pathogenesis of AMD, including oxidative stress, inflammation, and angiogenesis. METHODS: Confluent human RPE cells were stimulated with Abeta(1-40), or the reverse peptide Abeta(40-1), and genome wide changes in gene expression were studied with gene microarrays. Selected genes were verified by qRT-PCR and ELISA. Pathway analysis with gene set enrichment analysis (GSEA) and ingenuity revealed top functional pathways in RPE after Abeta(1-40) stimulation. RESULTS: RPE cells stimulated with Abeta(1-40) (0.3 microM) for 24 hours resulted in 63 upregulated and 22 downregulated previously known genes. The upregulated genes were predominantly in inflammatory and immune response categories, but other categories were also represented, including apoptosis, cell signaling, cell proliferation, and signal transduction. Categories of downregulated genes included immune response, transporters, metabolic functions and transcription factors. ELISA confirmed that secreted levels of IL-8 were two times higher than control levels. GSEA and ingenuity analysis confirmed that the top affected pathways in RPE cells after Abeta(1-40) stimulation were inflammation and immune response related. Surprisingly, few angiogenic pathways were activated at the doses and exposure times studied. CONCLUSIONS: Abeta(1-40) promotes RPE gene expression changes in pathways associated with immune response, inflammation, and cytokine and interferon signaling pathways. Results may relate to in vivo mechanisms associated with the pathogenesis of AMD.
PURPOSE: Age-related macular degeneration (AMD) is a common cause of irreversible vision loss in the elderly. The hypothesis was that in vitro stimulation of RPE cells with Abeta(1-40), a constituent of drusen, promotes changes in gene expression and cellular pathways associated with the pathogenesis of AMD, including oxidative stress, inflammation, and angiogenesis. METHODS: Confluent humanRPE cells were stimulated with Abeta(1-40), or the reverse peptide Abeta(40-1), and genome wide changes in gene expression were studied with gene microarrays. Selected genes were verified by qRT-PCR and ELISA. Pathway analysis with gene set enrichment analysis (GSEA) and ingenuity revealed top functional pathways in RPE after Abeta(1-40) stimulation. RESULTS:RPE cells stimulated with Abeta(1-40) (0.3 microM) for 24 hours resulted in 63 upregulated and 22 downregulated previously known genes. The upregulated genes were predominantly in inflammatory and immune response categories, but other categories were also represented, including apoptosis, cell signaling, cell proliferation, and signal transduction. Categories of downregulated genes included immune response, transporters, metabolic functions and transcription factors. ELISA confirmed that secreted levels of IL-8 were two times higher than control levels. GSEA and ingenuity analysis confirmed that the top affected pathways in RPE cells after Abeta(1-40) stimulation were inflammation and immune response related. Surprisingly, few angiogenic pathways were activated at the doses and exposure times studied. CONCLUSIONS: Abeta(1-40) promotes RPE gene expression changes in pathways associated with immune response, inflammation, and cytokine and interferon signaling pathways. Results may relate to in vivo mechanisms associated with the pathogenesis of AMD.
Authors: Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe Journal: Science Date: 2003-04-18 Impact factor: 47.728
Authors: Brett A Chromy; Richard J Nowak; Mary P Lambert; Kirsten L Viola; Lei Chang; Pauline T Velasco; Bryan W Jones; Sara J Fernandez; Pascale N Lacor; Peleg Horowitz; Caleb E Finch; Grant A Krafft; William L Klein Journal: Biochemistry Date: 2003-11-11 Impact factor: 3.162
Authors: Patrick T Johnson; Geoffrey P Lewis; Kevin C Talaga; Meghan N Brown; Peter J Kappel; Steven K Fisher; Don H Anderson; Lincoln V Johnson Journal: Invest Ophthalmol Vis Sci Date: 2003-10 Impact factor: 4.799
Authors: Don H Anderson; Kevin C Talaga; Alexander J Rivest; Ernesto Barron; Gregory S Hageman; Lincoln V Johnson Journal: Exp Eye Res Date: 2004-02 Impact factor: 3.467
Authors: Gareth T Higgins; Jiang Huai Wang; Peter Dockery; Philip E Cleary; H Paul Redmond Journal: Invest Ophthalmol Vis Sci Date: 2003-04 Impact factor: 4.799
Authors: Vamsi K Mootha; Cecilia M Lindgren; Karl-Fredrik Eriksson; Aravind Subramanian; Smita Sihag; Joseph Lehar; Pere Puigserver; Emma Carlsson; Martin Ridderstråle; Esa Laurila; Nicholas Houstis; Mark J Daly; Nick Patterson; Jill P Mesirov; Todd R Golub; Pablo Tamayo; Bruce Spiegelman; Eric S Lander; Joel N Hirschhorn; David Altshuler; Leif C Groop Journal: Nat Genet Date: 2003-07 Impact factor: 38.330
Authors: Dan-Ning Hu; Mingchao Bi; David Y Zhang; Fei Ye; Steven A McCormick; Chi-Chao Chan Journal: Invest Ophthalmol Vis Sci Date: 2014-08-14 Impact factor: 4.799
Authors: Jin-Dong Ding; Lincoln V Johnson; Rolf Herrmann; Sina Farsiu; Stephanie G Smith; Marybeth Groelle; Brian E Mace; Patrick Sullivan; Jeffrey A Jamison; Una Kelly; Ons Harrabi; Sangeetha Subbarao Bollini; Jeanette Dilley; Dione Kobayashi; Bing Kuang; Wenlin Li; Jaume Pons; John C Lin; Catherine Bowes Rickman Journal: Proc Natl Acad Sci U S A Date: 2011-06-20 Impact factor: 11.205